Skip to main content
Top
Published in: Journal of Clinical Psychology in Medical Settings 1/2011

01-03-2011 | Case Report

The Use of Psychoeducation for a Patient with Hepatitis C and Psychiatric Illness in Preparation for Antiviral Therapy: A Case Report and Discussion

Authors: Barry A. Hong, Carol S. North, David E. Pollio, Anna Abbacchi, Christine Debold, Sunday A. Adewuyi, Mauricio Lisker-Melman

Published in: Journal of Clinical Psychology in Medical Settings | Issue 1/2011

Login to get access

Abstract

The standard of care treatment for chronic hepatitis C viral infection (HCV) is a combination of pegylated interferon alfa and ribavirin for 24–48 weeks according to the virus genotype. This therapy is known to have multiple neuropsychiatric side effects. A major concern when evaluating a patient for HCV treatment with a known history of a psychiatric disorder is the risk that the patient’s psychiatric disorder will flare or become unmanageable. The possibility of precipitating depression, confusion, mania, psychosis, hallucinations, or suicidal ideation or attempt is frequently an obstacle to treatment. We present the case of a 50 year-old man with HCV and an extensive psychiatric history involving alcoholism, depression, and suicidality who participated in a psychoeducation group to help prepare him for treatment with pegylated interferon alfa/ribavirin therapy. Though the patient derived much benefit from the psychoeducation group, by the time of evaluation for HCV treatment two months after the group ended he had relapsed back into a depressive episode with suicidal thoughts. His acute psychiatric status made him unacceptable for pegylated interferon alfa/ribavirin therapy. Psychoeducation groups show promise for helping patients with chronic medical illness to be ready for and endure intensive medical treatment that has substantial psychiatric side effects. The challenge is to help patients overcome barriers to treatment, particularly psychosocial problems, because available treatments are increasingly effective.
Literature
go back to reference Bonaccorso, S., Marino, V., Biondi, M., Grimaldi, F., Ippoliti, F., & Maes, M. (2002). Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. Journal of Affective Disorders, 72, 237–241.PubMedCrossRef Bonaccorso, S., Marino, V., Biondi, M., Grimaldi, F., Ippoliti, F., & Maes, M. (2002). Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. Journal of Affective Disorders, 72, 237–241.PubMedCrossRef
go back to reference Broers, B., Helbling, B., Franc, A., Schmid, P., Chuard, C., Hadengue, A., et al. (2005). Barriers to interferon—A therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of Hepatology, 42, 323–328.PubMedCrossRef Broers, B., Helbling, B., Franc, A., Schmid, P., Chuard, C., Hadengue, A., et al. (2005). Barriers to interferon—A therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of Hepatology, 42, 323–328.PubMedCrossRef
go back to reference Cacoub, P., Rosenthal, E., Halfon, P., Sene, D., Perronne, C., & Pol, S. (2006). Treatment of hepatitis C virus and human immunodeficiency virus coinfection: From large trials to real life. Journal of Viral Hepatitis, 13, 678–682.PubMedCrossRef Cacoub, P., Rosenthal, E., Halfon, P., Sene, D., Perronne, C., & Pol, S. (2006). Treatment of hepatitis C virus and human immunodeficiency virus coinfection: From large trials to real life. Journal of Viral Hepatitis, 13, 678–682.PubMedCrossRef
go back to reference Cawthorne, C. H., Rudat, K. R., Burton, M. S., Brown, K. E., Luxon, B. A., Janney, C. G., et al.. (2002). Limited success of HCV antiviral therapy in United States veterans. American Journal of Gastroenterology, 97, 149–155. Cawthorne, C. H., Rudat, K. R., Burton, M. S., Brown, K. E., Luxon, B. A., Janney, C. G., et al.. (2002). Limited success of HCV antiviral therapy in United States veterans. American Journal of Gastroenterology, 97, 149–155.
go back to reference Chen, T., Ding, E. L., Seage, G. R., & Kim, A. Y. (2009). Meta-analysis: Increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. HIV/AIDS, 49, 1605–1615. Chen, T., Ding, E. L., Seage, G. R., & Kim, A. Y. (2009). Meta-analysis: Increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. HIV/AIDS, 49, 1605–1615.
go back to reference Delwaide, J., El Saouda, R., Gérard, C., Belaïche, J., & the Groupe Liègeois d’Etude des Virus Hépatotropes. (2005). Hepatitis C infection: Eligibility for antiviral therapies. European Journal of Gastroenterology and Hepatology, 17, 1185–1189.PubMedCrossRef Delwaide, J., El Saouda, R., Gérard, C., Belaïche, J., & the Groupe Liègeois d’Etude des Virus Hépatotropes. (2005). Hepatitis C infection: Eligibility for antiviral therapies. European Journal of Gastroenterology and Hepatology, 17, 1185–1189.PubMedCrossRef
go back to reference Dieperink, E., Willenbring, M., & Ho, S. B. (2000). Neuropsychiatric symptoms associated with hepatitis C and Interferon alpha: A review. American Journal of Psychiatry, 157, 867–876.PubMedCrossRef Dieperink, E., Willenbring, M., & Ho, S. B. (2000). Neuropsychiatric symptoms associated with hepatitis C and Interferon alpha: A review. American Journal of Psychiatry, 157, 867–876.PubMedCrossRef
go back to reference Dore, G. J., Hellard, M., Matthews, G. V., Grebely, J., Paul, S., Haber, P. S., et al. (2010). Clinical—Liver, pancreas, and biliary tract. Gastroenterology, 138, 123–135.PubMedCrossRef Dore, G. J., Hellard, M., Matthews, G. V., Grebely, J., Paul, S., Haber, P. S., et al. (2010). Clinical—Liver, pancreas, and biliary tract. Gastroenterology, 138, 123–135.PubMedCrossRef
go back to reference Falck-Ytter, Y., Kale, H., Mullen, K. D., Sarbah, S. A., Sorescu, L., & McCullough, A. J. (2002). Surprisingly small effect of antiviral treatment in patients with hepatitis C. Annals of Internal Medicine, 136, 288–292.PubMed Falck-Ytter, Y., Kale, H., Mullen, K. D., Sarbah, S. A., Sorescu, L., & McCullough, A. J. (2002). Surprisingly small effect of antiviral treatment in patients with hepatitis C. Annals of Internal Medicine, 136, 288–292.PubMed
go back to reference Fleming, C. A., Tumilty, S., Murray, J. E., & Nunes, D. (2005). Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: Need for team care. Clinical Infectious Diseases, 40, S349–S354.PubMedCrossRef Fleming, C. A., Tumilty, S., Murray, J. E., & Nunes, D. (2005). Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: Need for team care. Clinical Infectious Diseases, 40, S349–S354.PubMedCrossRef
go back to reference Fontana, R. J., Moyer, C. A., Sonnad, S., Lok, A. S. F., Sneed-Pee, N., Walsh, J., et al. (2001). Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. American Journal of Gastroenterology, 96, 170–178.PubMedCrossRef Fontana, R. J., Moyer, C. A., Sonnad, S., Lok, A. S. F., Sneed-Pee, N., Walsh, J., et al. (2001). Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. American Journal of Gastroenterology, 96, 170–178.PubMedCrossRef
go back to reference Freedman, K., & Nathanson, J. (2009). Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance abuse disorders. Expert Review of Anti-Infective Therapy, 7, 363–376.PubMedCrossRef Freedman, K., & Nathanson, J. (2009). Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance abuse disorders. Expert Review of Anti-Infective Therapy, 7, 363–376.PubMedCrossRef
go back to reference Grebely, J., Genoway, K. A., Raffa, J. D., Dhadwal, G., Rajan, T., Showler, G., et al. (2008). Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence, 93, 141–147.PubMedCrossRef Grebely, J., Genoway, K. A., Raffa, J. D., Dhadwal, G., Rajan, T., Showler, G., et al. (2008). Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence, 93, 141–147.PubMedCrossRef
go back to reference Grebely, J., Knight, E., Genoway, K. A., Viljoen, M., Khara, M., Elliott, D., et al. (2010). Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: A novel model incorporating multidisciplinary care and peer support. European Journal of Gastroenterology and Hepatology, 22, 270–277.PubMedCrossRef Grebely, J., Knight, E., Genoway, K. A., Viljoen, M., Khara, M., Elliott, D., et al. (2010). Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: A novel model incorporating multidisciplinary care and peer support. European Journal of Gastroenterology and Hepatology, 22, 270–277.PubMedCrossRef
go back to reference Hall, C. S., Charlebois, E. D., Hahn, J. A., Moss, A. R., & Bangsberg, D. R. (2004). Hepatitis C virus infection in San Francisco’s HIV-infected urban poor. Journal of General Internal Medicine;, 19, 357–365.PubMedCrossRef Hall, C. S., Charlebois, E. D., Hahn, J. A., Moss, A. R., & Bangsberg, D. R. (2004). Hepatitis C virus infection in San Francisco’s HIV-infected urban poor. Journal of General Internal Medicine;, 19, 357–365.PubMedCrossRef
go back to reference Ho, S. B., Nguyen, H., Tetrick, L. L., et al. (2001). Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. American Journal of Gastroenterology, 96, 157–164.PubMed Ho, S. B., Nguyen, H., Tetrick, L. L., et al. (2001). Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. American Journal of Gastroenterology, 96, 157–164.PubMed
go back to reference Kraus, M. R., Schafer, A., Faller, H., Csef, H., & Scheurlen, M. (2003). Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. Journal of Clinical Psychiatry, 64, 708–714.PubMedCrossRef Kraus, M. R., Schafer, A., Faller, H., Csef, H., & Scheurlen, M. (2003). Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. Journal of Clinical Psychiatry, 64, 708–714.PubMedCrossRef
go back to reference Liang, T. J. (1998). Combination therapy for hepatitis C infection. New England Journal of Medicine, 339, 1549–1550.PubMedCrossRef Liang, T. J. (1998). Combination therapy for hepatitis C infection. New England Journal of Medicine, 339, 1549–1550.PubMedCrossRef
go back to reference Maida, I., Soriano, V., Ramos, B., Ríos, P., González-Lahoz, J., & Núñez, M. (2005). Characteristics and prospects for hepatitis C therapy of an HIV–HCV coinfected population followed at a reference HIV center. HIV Clinical Trials, 6, 329–336.PubMedCrossRef Maida, I., Soriano, V., Ramos, B., Ríos, P., González-Lahoz, J., & Núñez, M. (2005). Characteristics and prospects for hepatitis C therapy of an HIV–HCV coinfected population followed at a reference HIV center. HIV Clinical Trials, 6, 329–336.PubMedCrossRef
go back to reference McLaren, M., Garber, G., & Cooper, C. (2008). Barriers to hepatitis C virus treatment in a Canadian HIV-Hepatitis C virus coinfection tertiary care clinic. Canadian Journal of Gastroenterology, 22, 133–137. McLaren, M., Garber, G., & Cooper, C. (2008). Barriers to hepatitis C virus treatment in a Canadian HIV-Hepatitis C virus coinfection tertiary care clinic. Canadian Journal of Gastroenterology, 22, 133–137.
go back to reference Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G. D., Vlahov, D., et al. (2008). Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health, 33, 126–133.PubMedCrossRef Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G. D., Vlahov, D., et al. (2008). Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health, 33, 126–133.PubMedCrossRef
go back to reference National Institute on Alcohol Abuse and Alcoholism. (1999). PAS-99-155: Hepatitis C infection and alcoholic liver disease. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism. National Institute on Alcohol Abuse and Alcoholism. (1999). PAS-99-155: Hepatitis C infection and alcoholic liver disease. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism.
go back to reference National Institutes of Health. (2002). National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002–June 10–12, 2002. Hepatology, 36, S3–S20. National Institutes of Health. (2002). National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002–June 10–12, 2002. Hepatology, 36, S3–S20.
go back to reference North, C. S., Pollio, D. E., Sachar, B., Hong, B., Isenberg, K., & Bufe, G. (1998). The family as caregiver: A group psychoeducation model for schizophrenia. American Journal of Orthopsychiatry, 68, 39–46.PubMedCrossRef North, C. S., Pollio, D. E., Sachar, B., Hong, B., Isenberg, K., & Bufe, G. (1998). The family as caregiver: A group psychoeducation model for schizophrenia. American Journal of Orthopsychiatry, 68, 39–46.PubMedCrossRef
go back to reference Renault, P. F., Hoofnagle, J. H., Park, Y., Mullen, K. D., Peters, M., Jones, D. B., et al. (1987). Psychiatric complications of long-term interferon alfa therapy. Archives of Internal Medicine, 147, 1577–1580.PubMedCrossRef Renault, P. F., Hoofnagle, J. H., Park, Y., Mullen, K. D., Peters, M., Jones, D. B., et al. (1987). Psychiatric complications of long-term interferon alfa therapy. Archives of Internal Medicine, 147, 1577–1580.PubMedCrossRef
go back to reference Rifai, M. A. (2006). Ethical impasses in the care of patients with hepatitis C. Psychosomatics, 47, 540–541.PubMedCrossRef Rifai, M. A. (2006). Ethical impasses in the care of patients with hepatitis C. Psychosomatics, 47, 540–541.PubMedCrossRef
go back to reference Schreiber, G. B., Busch, M. P., Kleinman, S. H., & Korelitz, J. J. (1996). The risk of transfusion-transmitted viral infections The Retrovirus Epidemiology Donor Study. New England Journal of Medicine, 334, 1685–1690.PubMedCrossRef Schreiber, G. B., Busch, M. P., Kleinman, S. H., & Korelitz, J. J. (1996). The risk of transfusion-transmitted viral infections The Retrovirus Epidemiology Donor Study. New England Journal of Medicine, 334, 1685–1690.PubMedCrossRef
go back to reference Seal, K. H., Currie, S. L., Shen, H., Anand, B. S., Bini, E. J., Brau, N., et al. (2007). Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: Does a history of injection drug use matter? Clinical Gastroenterology, 41, 199–205.CrossRef Seal, K. H., Currie, S. L., Shen, H., Anand, B. S., Bini, E. J., Brau, N., et al. (2007). Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: Does a history of injection drug use matter? Clinical Gastroenterology, 41, 199–205.CrossRef
go back to reference Spiegel, D., Bloom, J. R., & Yalom, I. (1981). Group support for patients with metastatic cancer A randomized outcome study. Archives of General Psychiatry, 38, 527–533.PubMed Spiegel, D., Bloom, J. R., & Yalom, I. (1981). Group support for patients with metastatic cancer A randomized outcome study. Archives of General Psychiatry, 38, 527–533.PubMed
go back to reference Thein, H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008). Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS, 22, 1979–1991.PubMedCrossRef Thein, H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008). Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS, 22, 1979–1991.PubMedCrossRef
go back to reference Thompson, V. V., Ragland, K. E., Hall, C. S., Morgan, M., & Bangsberg, D. R. (2005). Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS, 19, S208–S214.PubMedCrossRef Thompson, V. V., Ragland, K. E., Hall, C. S., Morgan, M., & Bangsberg, D. R. (2005). Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS, 19, S208–S214.PubMedCrossRef
go back to reference Yovtcheva, S. P., Rifai, M. A., Moles, J. K., & Van der Linden, B. J. (2001). Psychiatric comorbidity among hepatitis C positive patients. Psychosomatics, 42, 411–415.PubMedCrossRef Yovtcheva, S. P., Rifai, M. A., Moles, J. K., & Van der Linden, B. J. (2001). Psychiatric comorbidity among hepatitis C positive patients. Psychosomatics, 42, 411–415.PubMedCrossRef
Metadata
Title
The Use of Psychoeducation for a Patient with Hepatitis C and Psychiatric Illness in Preparation for Antiviral Therapy: A Case Report and Discussion
Authors
Barry A. Hong
Carol S. North
David E. Pollio
Anna Abbacchi
Christine Debold
Sunday A. Adewuyi
Mauricio Lisker-Melman
Publication date
01-03-2011
Publisher
Springer US
Published in
Journal of Clinical Psychology in Medical Settings / Issue 1/2011
Print ISSN: 1068-9583
Electronic ISSN: 1573-3572
DOI
https://doi.org/10.1007/s10880-011-9227-6

Other articles of this Issue 1/2011

Journal of Clinical Psychology in Medical Settings 1/2011 Go to the issue